Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA.
Company profile
Ticker
AKCA
Exchange
Website
CEO
Damien McDevitt
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Akcea Therapeutics UK Limited • Akcea Therapeutics Canada, Inc. • Akcea Therapeutics France SAS • Akcea Therapeutics Germany GmbH • Akcea Therapeutics Securities Corporation • Akcea Therapeutics Portugal, Unipessoal Lda, a Portuguese Company • Akcea Therapeutics Spain SL, a Spanish Company • Akcea Therapeutics Italia SRL ...
AKCA stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
23 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 20
POSASR
Automatic shelf registration (post-effective amendment)
13 Oct 20
8-K
Entry into a Material Definitive Agreement
13 Oct 20
SC 13E3/A
Going private transaction (amended)
13 Oct 20
SC 14D9/A
Tender offer solicitation (amended)
13 Oct 20
Latest ownership filings
Financial summary
Quarter (USD) | Jun 20 | Mar 20 | Sep 19 | Jun 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 138.13 mm | 138.13 mm | 138.13 mm | 138.13 mm | 138.13 mm | 138.13 mm |
Cash burn (monthly) | 9.19 mm | 5.44 mm | 17.03 mm | 13.97 mm | 11.14 mm | 11.75 mm |
Cash used (since last report) | 419.91 mm | 248.52 mm | 777.98 mm | 638.20 mm | 508.94 mm | 536.87 mm |
Cash remaining | -281.78 mm | -110.39 mm | -639.85 mm | -500.07 mm | -370.81 mm | -398.74 mm |
Runway (months of cash) | -30.7 | -20.3 | -37.6 | -35.8 | -33.3 | -33.9 |
Institutional ownership, Q1 2023
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 1.00 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
IONS Ionis Pharmaceuticals | 1.00 k | $0.00 |